NST-201 (estimated)
Hematological Malignancies
Preclinical/IND-enablingActive
Key Facts
Indication
Hematological Malignancies
Phase
Preclinical/IND-enabling
Status
Active
Company
About Novastage Pharmaceuticals
A clinical-stage biotech developing novel small molecule oncology drugs targeting difficult-to-treat cancers through structure-based design.
View full company profileTherapeutic Areas
Other Hematological Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| TYK-201 | TYK Medicines | Preclinical |
| TNB-655 | Tenacia Biotechnology | Preclinical |
| Undisclosed CAR-T Program | OBiO Technology | Phase 1/2 |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| PS-102 | Perimeter Systems, Inc. | Preclinical |
| JaxBio Hematology Cancer Test | JaxBio | Preclinical |
| YZY-002 | YZY Biopharma | Phase 1 |